Saving Magic Johnson: The Long and Complicated Race for Cures
Paul Beninger ’73 P’09 is an associate professor of Public Health & Community Medicine at Tufts University where he also directs the MD/MBA and MBS/MBA programs. He has more than three decades of experience as a regulator and member of the Senior Executive Service in the U.S. Food and Drug Administration (FDA), as a manager and executive in the pharmaceutical industry, including pharmacovigilance, and as a member of the academic community.
Beninger began his career in drug development in 1987 at the FDA, first as a reviewer and manager for drugs to combat HIV/AIDS and opportunistic infection and then as a division director for medical devices. He joined Merck & Company in 1995 and developed experience in regulatory affairs, medical affairs and drug safety in the areas of anti-infective drug and biological products, vaccines, anti-diabetic drug products and oncology drug products, before joining Genzyme as vice-president of pharmacovigilance in 2006 where he worked until 2017.
Beninger has published and spoken extensively on regulatory science, drug and vaccine safety, and pharmacovigilance. He is a topics editor (pharmacovigilance and pharmacoepidemiology) for Clinical Therapeutics, and a fellow of the American College of Physicians and the Infectious Disease Society of America.
A 1973 graduate of Claremont McKenna College where he studied mathematics, biology, and psychology, Beninger received his M.D. from the University of California, Davis and subsequently trained in internal medicine and infectious diseases. He also holds an MBA from St Joseph’s University in Philadelphia and a graduate certificate in epidemiology from Tufts.
View Video: YouTube with Paul Beninger '73 P'09